A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients

PHASE3RecruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

August 6, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions

Gastric Adenocarcinoma

Interventions

DRUG

CAR T cells

better PFS/OS data comparing to the other studies.

DRUG

Control

Chemo therapy by PI options.

Trial Locations (1)

RECRUITING

Chinese PLA General Hospital, Beijing, Beijing

All Listed Sponsors

lead

Suzhou Immunofoco Biotechnology Co., Ltd

INDUSTRY